220 related articles for article (PubMed ID: 28141868)
21. APOBEC3B expression in drug resistant MCF-7 breast cancer cell lines.
Onguru O; Yalcin S; Rosemblit C; Zhang PJ; Kilic S; Gunduz U
Biomed Pharmacother; 2016 Apr; 79():87-92. PubMed ID: 27044816
[TBL] [Abstract][Full Text] [Related]
22. Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*.
Zheng WQ; Lu J; Zheng JM; Hu FX; Ni CR
Steroids; 2001 Dec; 66(12):905-10. PubMed ID: 11711119
[TBL] [Abstract][Full Text] [Related]
23. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells.
Maruyama W; Shirakawa K; Matsui H; Matsumoto T; Yamazaki H; Sarca AD; Kazuma Y; Kobayashi M; Shindo K; Takaori-Kondo A
Biochem Biophys Res Commun; 2016 Sep; 478(3):1466-71. PubMed ID: 27577680
[TBL] [Abstract][Full Text] [Related]
24. Multiple roles of apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) in human tumors: a pan-cancer analysis.
Wu J; Li N; Zhu L; Zhen D; Li M; Chen H; Ye M; Wei Y; Shao G
BMC Bioinformatics; 2022 Aug; 23(1):312. PubMed ID: 35918642
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance.
Schmitt C; Lucius R; Synowitz M; Held-Feindt J; Hattermann K
Oncol Rep; 2018 Nov; 40(5):2742-2749. PubMed ID: 30226610
[TBL] [Abstract][Full Text] [Related]
26. Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses.
Verhalen B; Starrett GJ; Harris RS; Jiang M
J Virol; 2016 Jul; 90(14):6379-6386. PubMed ID: 27147740
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
28. Acute expression of human APOBEC3B in mice results in RNA editing and lethality.
Alonso de la Vega A; Temiz NA; Tasakis R; Somogyi K; Salgueiro L; Zimmer E; Ramos M; Diaz-Jimenez A; Chocarro S; Fernández-Vaquero M; Stefanovska B; Reuveni E; Ben-David U; Stenzinger A; Poth T; Heikenwälder M; Papavasiliou N; Harris RS; Sotillo R
Genome Biol; 2023 Nov; 24(1):267. PubMed ID: 38001542
[TBL] [Abstract][Full Text] [Related]
29. Aberrant APOBEC3B Expression in Breast Cancer Is Linked to Proliferation and Cell Cycle Phase.
Roelofs PA; Timmermans MAM; Stefanovska B; den Boestert MA; van den Borne AWM; Balcioglu HE; Trapman AM; Harris RS; Martens JWM; Span PN
Cells; 2023 Apr; 12(8):. PubMed ID: 37190094
[TBL] [Abstract][Full Text] [Related]
30. Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.
Radmanesh H; Spethmann T; Enßen J; Schürmann P; Bhuju S; Geffers R; Antonenkova N; Khusnutdinova E; Sadr-Nabavi A; Shandiz FH; Park-Simon TW; Hillemanns P; Christiansen H; Bogdanova N; Dörk T
Breast Cancer Res Treat; 2017 Feb; 162(1):31-37. PubMed ID: 28062980
[TBL] [Abstract][Full Text] [Related]
31. Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases.
Durfee C; Temiz NA; Levin-Klein R; Argyris PP; Alsøe L; Carracedo S; Alonso de la Vega A; Proehl J; Holzhauer AM; Seeman ZJ; Liu X; Lin YT; Vogel RI; Sotillo R; Nilsen H; Harris RS
Cell Rep Med; 2023 Oct; 4(10):101211. PubMed ID: 37797615
[TBL] [Abstract][Full Text] [Related]
32.
Sieuwerts AM; Doebar SC; de Weerd V; Verhoef EI; Beauford CM; Agahozo MC; Martens JWM; van Deurzen CHM
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31357602
[TBL] [Abstract][Full Text] [Related]
33. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
Ba JL; Liu CG; Jin F
Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
[TBL] [Abstract][Full Text] [Related]
34. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
35. The roles of APOBEC3B in gastric cancer.
Zhang J; Wei W; Jin HC; Ying RC; Zhu AK; Zhang FJ
Int J Clin Exp Pathol; 2015; 8(5):5089-96. PubMed ID: 26191203
[TBL] [Abstract][Full Text] [Related]
36. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
37. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
[TBL] [Abstract][Full Text] [Related]
38. Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort.
Vitiello GAF; de Sousa Pereira N; Amarante MK; Banin-Hirata BK; Campos CZ; de Oliveira KB; Losi-Guembarovski R; Watanabe MAE
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1523-1532. PubMed ID: 32285256
[TBL] [Abstract][Full Text] [Related]
39. Evidence for APOBEC3B mutagenesis in multiple human cancers.
Burns MB; Temiz NA; Harris RS
Nat Genet; 2013 Sep; 45(9):977-83. PubMed ID: 23852168
[TBL] [Abstract][Full Text] [Related]
40. APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma.
Kosumi K; Baba Y; Ishimoto T; Harada K; Nakamura K; Ohuchi M; Kiyozumi Y; Izumi D; Tokunaga R; Taki K; Higashi T; Miyata T; Shigaki H; Kurashige J; Hiyoshi Y; Iwatsuki M; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Oki E; Watanabe M; Baba H
Med Oncol; 2016 Mar; 33(3):26. PubMed ID: 26880326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
